Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Cash from Investing Activities (2017 - 2021)

GT Biopharma (GTBP) has disclosed Cash from Investing Activities for 4 consecutive years, with $3.0 million as the latest value for Q4 2021.

  • On a quarterly basis, Cash from Investing Activities changed N/A to $3.0 million in Q4 2021 year-over-year; TTM through Dec 2021 was $3.0 million, a 1395.5% increase, with the full-year FY2024 number at $12.9 million, up 741.76% from a year prior.
  • Cash from Investing Activities was $3.0 million for Q4 2021 at GT Biopharma, up from $200000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $3.0 million in Q4 2021 to a low of -$4000.0 in Q4 2017.
  • A 4-year average of $637400.0 and a median of $2000.0 in 2019 define the central range for Cash from Investing Activities.